Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

被引:9
作者
Najarian, Dean [1 ]
Turkoz, Ibrahim [2 ,8 ]
Knight, R. Karl
Galderisi, Silvana [3 ]
Lamaison, Hector F. [4 ]
Zalitacz, Piotr [5 ]
Aravind, Suresh [2 ,7 ]
Richarz, Ute [6 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
Long-term efficacy; schizophrenia; long-acting injectable; open-label extension; paliperidone palmitate 6-month; ACTING INJECTABLE ANTIPSYCHOTICS; PALMITATE; RELAPSE; REHOSPITALIZATION; NONADHERENCE; MEDICATION; ADHERENCE; PLACEBO;
D O I
10.1093/ijnp/pyad028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条
  • [21] Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence
    Si, Tianmei
    Li, Nan
    Lu, Huafei
    Cai, Shangli
    Zhuo, Jianmin
    Correll, Christoph U.
    Zhang, Lili
    Feng, Yu
    JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (06) : 691 - 701
  • [22] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [23] Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
    Giron-Hernandez, Cesar
    Han, Joong Hee
    Alberio, Roberta
    Singh, Arun
    Garcia-Portilla, Maria Paz
    Pompili, Maurizio
    Knight, R. Karl
    Richarz, Ute
    Gopal, Srihari
    Antunes, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 895 - 906
  • [24] Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting
    Chung, Young-Chul
    Yang, Yen Kuang
    Sulaiman, Ahmad Hatim
    Bergmans, Paul
    Tan, Wilson
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (03) : 427 - 439
  • [25] Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
    Fleischer, David M.
    Shreffler, Wayne G.
    Campbell, Dianne E.
    Green, Todd D.
    Anvari, Sara
    Assa'ad, Amal
    Begin, Philippe
    Beyer, Kirsten
    Bird, J. Andrew
    Brown-Whitehorn, Terri
    Byrne, Aideen
    Chan, Edmond S.
    Cheema, Amarjit
    Chinthrajah, Sharon
    Chong, Hey Jin
    Davis, Carla M.
    Ford, Lara S.
    Gagnon, Remi
    Greenhawt, Matthew
    Hourihane, Jonathan O'B
    Jones, Stacie M.
    Kim, Edwin H.
    Lange, Lars
    Lanser, Bruce J.
    Leonard, Stephanie
    Mahler, Vera
    Maronna, Andreas
    Nowak-Wegrzyn, Anna
    Oriel, Roxanne C.
    O'Sullivan, Michael
    Petroni, Daniel
    Pongracic, Jacqueline A.
    Prescott, Susan L.
    Schneider, Lynda C.
    Smith, Peter
    Staab, Doris
    Sussman, Gordon
    Wood, Robert
    Yang, William H.
    Lambert, Romain
    Peillon, Aurelie
    Bois, Timothee
    Sampson, Hugh A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (04) : 863 - 874
  • [26] Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
    Saito, Takuya
    Hyodo, Yohei
    Sakaguchi, Reiko
    Nakamura, Hiroshi
    Ishigooka, Jun
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) : 24 - 35
  • [27] Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)
    Partinen, Markku
    Hirvonen, Kari
    Jama, Leni
    Alakuijala, Anniina
    Hublin, Christer
    Tamminen, Ilkka
    Koester, Juergen
    Reess, Juergen
    SLEEP MEDICINE, 2008, 9 (05) : 537 - 541
  • [28] Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
    Inada, Ken
    Yamada, Sakiko
    Akiyoshi, Hisashi
    Kojima, Yoshitsugu
    Iwashita, Shuichi
    Ishigooka, Jun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 2267 - 2275
  • [29] Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
    Durgam, Suresh
    Landbloom, Ronald P.
    Mackle, Mary
    Wu, Xiao
    Mathews, Maju
    Nasrallah, Henry A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2021 - 2035
  • [30] Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
    Xenofon Baraliakos
    Désirée van der Heijde
    Joachim Sieper
    Robert D. Inman
    Hideto Kameda
    Yihan Li
    Xianwei Bu
    Anna Shmagel
    Peter Wung
    In-Ho Song
    Atul Deodhar
    Arthritis Research & Therapy, 25